Elastin-like polypeptides are a class of naturally derived and non-immunogenic biomaterials that are widely used in drug delivery and tissue engineering. Elastin-like polypeptides undergo temperaturemediated inverse phase transitioning, which allows them to be purified in a relatively simple manner from bacterial expression hosts. Being able to genetically encode elastin-like polypeptides allows for the incorporation of bioactive peptides, thereby functionalizing them. Here, we report the synthesis of a biologically active epidermal growth factor-elastin-like polypeptide fusion protein that could aid in wound healing. Epidermal growth factor plays a crucial role in wound healing by inducing cell proliferation and migration. The use of exogenous epidermal growth factor has seen success in the treatment of acute wounds, but has seen relatively minimal success in chronic wounds because the method of delivery does not prevent it from diffusing away from the application site. Our data show that epidermal growth factor-elastin-like polypeptide retained the biological activity of epidermal growth factor and the phase transitioning property of elastin-like polypeptide. Furthermore, the ability of the epidermal growth factor-elastin-like polypeptide to self-assemble near physiological temperatures could allow for the formation of drug depots at the wound site and minimize diffusion, increasing the bioavailability of epidermal growth factor and enhancing tissue regeneration.
Introduction
Epidermal growth factor (EGF) is a 53-amino acid single-chain polypeptide discovered by Dr Stanley Cohen in 1962 while studying the effects of mice submaxillary gland extract on newborn mice. 1, 2 EGF is a member of a family of growth factors, the EGF family, that are able to bind to the epidermal growth factor receptor (EGFR), a tyrosine kinase transmembrane protein found throughout the epidermis. Upon binding EGF, the EGFR undergoes dimerization and autophosphorylation, activating the mitogen-activated protein kinase (MAPK) pathway. Ultimately, activation of the MAPK pathway influences the phosphorylation of various transcription factors and calcium release of protein kinase C. Furthermore, activation and dimerization of the EGFR due to EGF binding has been shown to play a crucial role in epidermal regeneration and corneal epithelial regeneration through enhancing epithelial cell proliferation and migration, stimulating the production of extracellular matrix proteins, and increasing fibroblasts proliferation. 3 The use of exogenous EGF in acute wound healing was originally examined in 1973 by Savage and Cohen, when they demonstrated corneal epithelial hyperplasia can be induced using EGF. 4 Since then, the use of exogenous EGF has shown promise in the treatment of acute surgical wounds in rabbits, 5 corneal epithelial wounds, [6] [7] [8] and partial thickness burn wounds. 9 However, the use of exogenous EGF to aid in the treatment of chronic wounds, such as diabetic ulcers or venous ulcers, has not been as successful. Exudative fluid withdrawn from chronic wounds has shown, compared to acute wounds, an increased level in protease activity and diminished EGF activity. 10, 11 This hints at the possibility EGF is degraded by excessive protease activity within the microenvironment of chronic wounds. Furthermore, Falanga et al. 12 demonstrated the topical administration of aqueous EGF solutions to venous ulcers does not cause a statistically significant decrease in wound area after a period of 10 weeks. Due to these studies, alternative delivery systems have been investigated.
As aforementioned, the microenvironment in chronic wounds leads to the excessive degradation of growth factors that enter the wound. The high rate of degradation means there is not a high enough concentration of EGF present at the wound site to make a significant difference in healing, and the growth factor is not present in the wound long enough for its presence to be detected. 13 Additionally, when EGF is administered using simple bolus delivery methods, such as topical application 12 or intralesional injections, 14 it is able to easily diffuse away from the wound decreasing the local concentration of EGF, thus minimizing its impact on wound healing. This can lead to using large quantities of EGF and having to reapply the treatment continuously, potentially leading to tumor development and making the therapy expensive. 13 To combat these issues, delivery systems utilizing hydrogels with EGF encapsulated within the polymer network have been investigated. While there has been moderate success using this method, there is little control over the release of EGF from the polymer network, resulting in a burst release profile of EGF. 15 While there may be some instances where a burst release profile is preferred, most applications require the ability to control the release of EGF to ensure the growth factor is present throughout the healing process. 6 To achieve this, growth factor delivery vehicles that allow for the covalent binding, or at least physical interactions, between growth factors and a scaffold are developed. 13 Elastin-like polypeptides (ELPs) are a class of genetically encodable polymers that possess temperature-dependent phase transition properties. 16 The biocompatibility and ability to form nanostructures makes ELPs ideal for drug delivery and in vivo applications. Additionally, since ELPs are genetically encodable, it is relatively simple to fuse biologically active peptides or proteins to ELPs creating ELP fusion proteins. 17, 18 These ELP fusion proteins have been shown to retain not only the inverse phase transition property of traditional ELPs but also the biological activity of the fused peptide. 19 Hence, ELP fusion proteins have the potential to serve as all-in-one drug delivery systems, containing the drug and delivery vehicle without the need for chemical conjugation.
Here, we report the creation of a biologically active EGF-ELP fusion protein that could address the issues connected with the use of exogenous EGF in regenerative medicine. Currently, the administration of exogenous EGF is carried out by either a simple injection or topical application. Unfortunately, with these techniques, EGF can be rapidly degraded and can diffuse away from the application site with relative ease, leading to a decreased local concentration of EGF and minimal improvements as far as tissue regeneration is concerned. We report that the biological activity of EGF was retained in the fusion as well as the physical properties of ELPs. We further show that the ELPs in the fusion result in aggregation of the protein at its transition temperature. Thus, the fusion protein was rapidly and easily purified by inverse temperature cycling (ITC). 20 This represents a seamless production of a functionalized biomaterial in one step eliminating the need of physically or chemically conjugating growth factors or other bioactive proteins. Due to the polymeric ELP backbone, the fusion protein can also act as a scaffold for tissue engineering as well as a drug since it contains EGF. Finally, aggregates of EGF-ELP can also act as drug depots of EGF limiting the loss of the growth factor due to diffusion.
Materials and methods

Materials
Restriction enzymes and other materials used for cloning were purchased from New England Biolabs (New England Biolabs, Ipswich, MA). EGF and V 40 C 2 (ELP) genes were purchased from GenScript (Piscataway, NJ; peptide sequences are described in Table 1 ). DNA purification and gel extraction were conducted using kits produced by Qiagen (Germantown, MD). Top10f-competent Escherichia coli used for DNA cloning and BLR(DE3)-competent E. coli used for fusion protein expression were purchased by Invitrogen (Carlsbad, CA).
For cell culture purposes, fetal bovine serum (FBS) and Dulbecco's Modified Eagle's Medium (DMEM) were purchased from Life Technologies (Carlsbad, CA), and antibiotic-antimycotic (AA) solution was purchased from Corning (Mediatech, Manassas, VA). Dr Eric Haura from Moffitt Cancer Center generously donated A549 adenocarcinomic alveolar basal epithelial cells and A431 epidermoid carcinoma cells. Human skin fibroblasts were purchased from ATCC (Manassas, VA).
Fluorescent photographs for migration and cell counting experiments were taken using an EVOS® FL Digital Inverted Microscope (Life Technologies). ImageJ (National Institutes of Health) was used to analyze fluorescent images. Fluorescent staining of cell cytoplasm was conducted using ethidium homodimer, purchased from Life Technologies. Cell nuclei were fluorescently stained using NucBlue from Life Technologies.
An Eon™ High Performance Microplate Spectrophotometer from Biotek was used for optical density readings at 350 nm (OD, 350), while a Synergy Multi-Mode Reader from Biotek (Winooski, VT) was used for fluorescence readings during A549 and fibroblasts proliferation 
EGF-ELP gene construction
The EGF gene was sent in a pUC57 plasmid with PflMI and BglI restriction enzyme sites flanking the gene. PflMI and BglI were used to remove the EGF gene from the pUC57 plasmid, and BglI was used to linearize the ELP pUC19 plasmid. The EGF gene was ligated into the linearized ELP pUC19 plasmid and transformed into Top10f-competent cells. The ligation was carried out so that EGF was at the N-terminus of the fusion protein.
The EGF-ELP pUC19 plasmid was then cut using the restriction enzymes PflMI and BglI to excise the EGF-ELP gene. The EGF-ELP gene was then ligated into a linearized pET25b(+) expression vector and transformed into Top10f-competent cells. The EGF-ELP pET25b(+) vector was sent for sequencing to confirm the EGF-ELP gene was successfully ligated and no mutations were present. The EGF-ELP pET25b(+) vector was then transformed into BLR(DE3)-competent cells for fusion protein expression.
EGF-ELP fusion protein expression and purification
BLR(DE3)-competent cells containing the EGF-ELP pET25(b+) plasmid were cultured in 50 mL of TB media (yeast extract: 24 g/L, tryptone: 12 g/L, potassium phosphate monobasic: 2.31 g/L, potassium phosphate monobasic: 12.54 g/L, proline: 11.5 g/L, glycerol: 4 mL/L, and carbenicillin: 100 µg/mL) overnight. The next day, the starter culture was added to 1 L of fresh TB media and cultured for 18 h at 37°C and 180 r/min. E. coli was collected by centrifugation (3000g, 4°C, 20 min) and resuspended in 160 mL of 4°C phosphate-buffered saline (PBS). Bacteria was then lysed using a Model 505 Sonic Dismembrator (Fisher Scientific, Waltham, MA) set to run at 50% amplitude for 12 min cycles (three cycles total, pulse on 59 s, pulse off 59 s). After each cycle, the bacterial lysate was cooled at 4°C for 40 min. To remove cellular debris, the bacterial lysate was centrifuged (20,000g, 4°C, 20 min) and the supernatant containing EGF-ELP was collected.
After collecting the supernatant, EGF-ELP was purified using ITC. The supernatant was supplemented with 1 M NaCl and placed in a water bath at 45°C for 40 min. The EGF-ELP solution underwent a hot spin (20,000g, 40°C, 10 min), after which the supernatant was discarded and the pellet was resuspended in 100 mL PBS containing 10 mM dithiothreitol (DTT) at 4°C. DTT served as a reducing agent to prevent the formation of disulfide bonds, which would decrease the solubility of the EGF-ELP. Prior to cold spins (20,000g, 4°C, 20 min), the EGF-ELP solution was cooled at 4°C for 1 h. The cycle of hot and cold spins was conducted three times, or until cellular debris was no longer visible after centrifugation.
After the last hot spin, the EGF-ELP pellet was resuspended in 50 mL deionized (DI) water at 4°C. The EGF-ELP solution was then dialyzed against DI H 2 O for 18 h at 4°C to remove any salts or DTT that may be present. After dialysis, the EGF-ELP was lyophilized.
Total protein stain and western blot analysis
Total protein stains and western blot analysis were conducted using SDS-PAGE. Samples were taken from various stages of ITC and were analyzed by SDS-PAGE. For western blots, anti-EGF antibody was used to label EGF-ELP. Horseradish peroxidase (HRP)-linked anti-rabbit antibody was used to label anti-EGF antibody, and a chemiluminescent signal was produced using LumiGLO® reagent and peroxide.
EGF-ELP transition temperature
EGF-ELP was dissolved in cold PBS (~4°C) to create a 5 µM solution and was then filtered using a 0.45-µm filter. DLS was used to analyze the sample as the temperature was increased from 10°C to 40°C in 5°C increments using the Zetasizer Nano S (Malvern instruments, Malvern, UK). The sample was allowed to equilibrate for 15 min and the derived count rate (kcps) was recorded twice at each temperature.
EGF-ELP hysteresis
EGF-ELP was diluted in cold PBS (~4°C) to a concentration of 15 µM. Then, 100 µL was loaded in a round-bottom 96-well plate, which was then placed in the spectrophotometer. The optical density at 350 nm (OD, 350) was measured as the EGF-ELP solution was heated from 26°C to 42°C in increments of 2°C. The OD 350 was also measured as the solution was cooled from 42°C to 26°C in increments of 2°C. The EGF-ELP solution was shaken for 30 s and allowed to equilibrate for 10 min at each temperature before the OD 350 was measured.
EGF-ELP size characterization
A 5 µM EGF-ELP solution was prepared using cold PBS (~4°C) and filtered using a 0.45-µm filter. DLS was used to analyze the EGF-ELP solution at 15°C (below the T t ) and 37°C (above the T t ) using the Zetasizer Nano S (Malvern instruments, Malvern, UK). This apparatus produces a speckle pattern by illuminating the particles with a laser. The scattering intensity at a specific angle fluctuates with time, which is detected using a sensitive avalanche photodiode detector (APD). A digital autocorrelator generates a correlation function by analyzing the intensity changes. Particle size distribution can then be deduced by the correlation function. The EGF-ELP sample equilibrated at each temperature for 15 min prior to being analyzed. After equilibration, the EGF-ELP solution was analyzed three times at each temperature. The particle size distribution (mean intensity) and polydispersity index (PDI) were calculated by the Zetasizer Nano S software.
A549 proliferation and migration
For the A549 proliferation study, A549 cells were seeded in a 48-well plate at 15,000 cells/well in DMEM + 10% FBS + 1% AA for 24 h. Next, cells were washed with 1× PBS and serum starved for 24 h. Cells were then treated with serum-free media and various amounts of ELP, EGF-ELP, and recombinant EGF (rEGF) for 48 h. Cellular proliferation was measured by quantifying the DNA content of cells in response to the treatment by the bromodeoxyuridine (BrDU) assay using a kit as per the manufacturer's recommendations (BD Biosciences, San Jose, CA). Briefly, 24 h into treatment, BrdU was added to the wells. After 48 h, the incorporated BrDU which is a direct measure of DNA synthesis was labeled by an antibody and quantified by measuring the fluorescence at 450 nm.
For the migration experiment, cells were prepared by seeding 10,000 cells/well in DMEM + 10% FBS + 1% AA. After 24 h, cells were washed with 1× PBS and serum starved for an additional 24 h. Following serum starvation, cells were treated with EGF-ELP or ELP (5 µM). After 48 h of treatment, cells were treated with calcein and incubated at 37°C for 30 min. After incubation, photographs were taken at 10× and 20×.
Inhibition of A431 cellular proliferation
A431 epidermoid carcinoma cells were seeded in a 48-well plate at 10,000 cells/well in DMEM + 10% FBS + 1% AA for 24 h. Cells were then washed with 1× PBS and cultured in 2% FBS for 24 h. After 24 h, cells were treated with different concentrations of ELP and EGF-ELP in 2% FBS for 48 h. Cell nuclei were then stained with NucBlue (2 drops/mL media) (Life Technologies, Carlsbad, MA) and dead cells were stained with ethidium homodimer (1:500 dilution). Cells were then incubated at 37°C for 30 min. Nine pictures/well were taken at 10× magnification. Images were then analyzed using ImageJ software and a macro created by Iglesias and Koria. 21
Human skin fibroblast proliferation
Human skin fibroblasts were seeded in a 48-well plate with 20,000 cells/well in DMEM + 10% FBS + 1% AA. After 24 h, cells were serum starved in DMEM + 1% AA for 48 h. Following serum starvation, cells were treated with various amounts of EGF-ELP, ELP, and rEGF for 48 h in serumfree culture. Following treatment, cell proliferation was measured by quantifying the DNA content using a Hoechst 33258 assay (Life Technologies, Carlsbad, CA). Fluorescence changes were recorded using an excitation wavelength of 360 nm and an emission wavelength of 460 nm.
Statistical analysis
Statistical significance for biological activity assays was determined using the p-value calculated from analysis of variance (ANOVA).
Results
EGF-ELP is purified using inverse transition cycling
The total protein stain at various stages of the purification procedure shows successful purification of the protein by inverse transition cycling (ITC) (Figure 1(a) ). The sample in Lane 1 was taken from the bacterial lysate and contains high protein content, as shown by the intense signal and lack of distinct protein bands. The samples used in Lane 2 and Lane 3 were taken during the later stages of ITC, with the sample in Lane 3 being taken after Lane 2. The protein content in Lane 2 appears to be similar to the protein found in Lane 1, indicating high protein content. In contrast, Lane 3 contains less protein than the bacterial lysate and Lane 2, and a single band between 15 and 35 kDa is apparent. This demonstrates that ITC does remove impurities as the cycle progresses. Lane 4 contains the lyophilized EGF-ELP. The protein sample at this stage has been through the entire ITC process, dialyzed for 18 h, and lyophilized. Lane 4 comprises a single band at approximately 30 kDa, demonstrating it is possible to successfully remove impurities while purifying the EGF-ELP using ITC.
To confirm EGF-ELP was the protein isolated during ITC, samples from several stages of ITC were taken and underwent western blot analysis using anti-EGF antibody (Figure 1(b) ). The protein bands near 30 kDa indicate the presence of EGF-ELP (Figure 1(b) , MW = 26.7 kDa). The western blot shows the EGF-ELP did not solubilize completely as it is present in the cold pellet (Lane 2) and cold supernatant (Lane 3) in roughly equal amounts after the first cold centrifugation. Additionally, the protein bands present in the hot pellet (Lane 4) and hot supernatant (Lane 5) indicate the EGF-ELP is present in both samples after the first hot centrifugation. However, the signal in the hot pellet is more intense than the signal in the hot supernatant, indicating there is a larger quantity of the EGF-ELP in the hot pellet. Finally, the band seen in the lyophilized product demonstrates the final product contains the EGF-ELP (Lane 6), and the minimal background noise indicates there are relatively few impurities present in the lyophilized EGF-ELP product.
EGF-ELP transitions below physiological temperature
The transition temperature of the EGF-ELP was determined using DLS. The mean count rate of a 25 µM sample was recorded over a temperature range of 10°C-40°C in 5°C intervals (Figure 2 ). An increase in derived count rate corresponds to the transition of EGF-ELP from monomers to aggregates. From 10°C to 25°C, the mean count rate stays fairly constant at approximately 200 kilocounts/s (kcps). Once the temperature reached 30°C, the mean count rate increased from 200 to 850 kcps, indicating the aggregation of EGF-ELPs. The transition temperature likely lies between 30°C and 35°C. As the temperature was increased further to 35°C and 40°C, the mean count rate increased to 1250 and 2600 kcps, respectively. The continued increase in mean count rate denotes a further increase in EGF-ELP aggregate size. 
EGF-ELP demonstrates hysteresis behavior
To further determine whether the phase transition behavior of EGF-ELP is elastic similar to ELPs, we measured the optical density of a 15 µM solution of EGF-ELP solution at increasing and decreasing temperatures (Figure 3 ). The OD 350 was measured as the EGF-ELP solution was heated from 26°C to 42°C and then cooled from 42°C to 26°C in increments of 2°C. As the sample was heated from 26°C to 42°C, the OD350 value increased from 0.152 (±0.006) to 1.322 (±0.004), indicating the formation of EGF-ELP aggregates. However, the OD 350 value did not increase significantly until the sample was heated to 38°C. When the solution was cooled from 42°C to 26°C, the OD 350 value decreased from 1.322 (±0.004) to 0.241 (±0.018), showing the EGF-ELP was able to be solubilized after forming aggregates. Also, the EGF-ELP during cooling did not follow the same path as heating, thereby displaying a hysteresis behavior in phase transition. 
EGF-ELP partially solubilizes below the transition temperature
DLS was conducted below the transition temperature (4°C, Figure 4(a) ) and above the transition temperature (37°C, Figure 4(b) ) to determine the size of EGF-ELP monomers and aggregates and determine the particle size distribution. Three measurements were recorded at each temperature. At 4°C, the Z-average value of the EGF-ELP was 61.00 nm with an average PDI value of 0.377 (data not shown).
Below the transition temperature, we observed that the particle size distribution is multimodal, with an approximate range of 5.61-5560 nm (Figure 4(a) ). Relative maxima for mean intensity are found at 11.7 nm (4.7%) and 5560 nm (3.8%) with an absolute maximum at 142 nm (4.9%). When DLS was conducted at 37°C, the Z-average of the EGF-ELP aggregates was determined to be 684.15 nm with an average PDI of 0.055 (data not shown). The relatively low PDI value indicates the Z-average value is reliable and that the data are monodispersed. Also, above the transition temperature, the particle size distribution is monomodal and monodispersed, with a range of approximately 459-1100 nm (Figure 4(b) ). The maximum mean intensity value was found to occur at 712 nm with a mean intensity value of 25.7%.
EGF-ELP retained the biological activity of the fused EGF
To test the biological activity of the fused EGF in the EGF-ELP, we performed several cellular assays involving multiple cells lines. Each assay confirmed that the EGF in the fused EGF-ELP was active. These assays are described below.
EGF-ELP induces proliferation of A549 cells. rEGF has been shown to induce proliferation of nonsmall cell lung cancer (NSCLC) cell lines, such as A549 adenocarcinomic epithelial cells. NSCLC cell lines overexpress the EGFR, making them ideal to test the biological activity of the EGF-ELP. 22 Cell proliferation was measured using a BrdU assay to quantify the synthesis of new DNA after 48 h of treatment. The results show that EGF-ELP retained the biological activity of rEGF by increasing cellular proliferation nearly 20% when compared to the control after 48 h of treatment for all three concentrations used ( Figure 5(a) ).
EGF-ELP induces migration of A549 cells.
EGF has also been shown to induce the migration of A549 cells. 23 To further investigate the biological activity of the EGF-ELP, A549 cells were treated with serum-free media as a control, ELP or EGF-ELP (5 µM) for 48 h, after which they were stained with calcein and photographed to observe differences in migration patterns. Treatment with ELP did not produce any change in cell or cell colony morphology when compared to the control group, with both forming tightly packed colonies. Treatment with EGF-ELP induced a change in cell morphology compared to the control and ELP treatment. A549 cells treated with EGF-ELP appear to have an elongated morphology and do not form distinct colonies as the control and ELP-treated cells do ( Figure 5(b) ).
EGF-ELP inhibits proliferation of A431 cells.
It has been demonstrated that EGF is able to inhibit cell proliferation of certain cells overexpressing the EGFR, such as A431 epidermoid carcinoma cells. 24 To determine whether the EGF-ELP was biologically active, A431 cells were treated with various concentrations of ELP or EGF-ELP for 48 h, after which the number of live cells was counted. When A431 cells were treated with EGF-ELP (5, 10, and 15 µM), the number of live cells counted decreased by nearly 50% when compared to the untreated control and the ELP controls ( Figure  5(c) ). ELP controls did not experience a statistically significant increase or decrease in cell count after 48 h of treatment when compared to the untreated control.
Induction of human skin fibroblast proliferation using EGF-ELP. EGF has been shown to promote cellular proliferation in human fibroblast. 25, 26 So to further test the biological activity of the EGF-ELP, human skin fibroblasts were treated with EGF-ELP for 48 h and a Hoechst assay was performed to determine cell proliferation. The data show that the EGF-ELP does induce proliferation of human skin fibroblasts when compared to serum-free controls and ELP controls. Both EGF-ELP treatments, 5 and 15 µM, caused an approximately 45% increase in cell proliferation. ELP treatments did not cause any statistically significant increase in fibroblast proliferation ( Figure 5(d) ).
Discussion
The aim of this study was to create a recombinant biologically active biomaterial that could be used for drug delivery and tissue engineering applications. Exogenous EGF has been used in regenerative medicine with moderate success to treat acute wounds, but minimal success has been seen in chronic wounds. This has been attributed to the harsh microenvironment in chronic wounds, which leads to enhanced degradation of exogenous growth factors. 10, 11 Additionally, EGF is typically administered in a bolus solution, which allows EGF to easily diffuse away from the injection site. Both increased degradation and diffusion lead to poor bioavailability of the growth factor; hence, minimal improvements are seen with EGF administration in chronic wounds. 12 The EGF-ELP fusion protein we have fabricated may assist in overcoming these hurdles in EGF administration. To start, the ability to undergo self-assembly at physiological temperature may allow for the formation of drug depots at the injection site, increasing the local concentration of EGF and possibly limiting diffusion of EGF. In addition, the EGF-ELP fusion protein can be used to create EGF-ELP infused hydrogels, similar to fibrin hydrogels infused with EGF-ELP fusion protein. 19 The ELP domain of the EGF-ELP could also be cross-linked with a scaffold to immobilize EGF, thereby creating a concentration gradient promoting cell migration and proliferation into , and EGF-ELP. Cell proliferation was quantified by measuring the DNA content as described in section "Materials and methods." (b) Cell migration was observed by treating A549 cells with SF control media, ELP (5 µM), or EGF-ELP (5 µM) for 48 h. Cells were then stained with calcein to aid in visualization of cell morphology. Clearly, the colonies are more scattered and there are longer distances between the cells that show migratory phenotype in the EGF-ELP sample. (c) A431 cells were treated with control media (2% serum), ELP, or EGF-ELP for 48 h, after which cell nuclei were stained with NucBlue and dead cell nuclei were stained with ethidium homodimer. (d) Human skin fibroblasts were treated for 48 h with SF control media, ELP, or EGF-ELP, after which DNA was quantified to evaluate cell proliferation as described in section "Materials and methods." For all cell proliferation assays, "*" denotes a p-value ⩽ 0.05 and "**" denotes a p-value ⩽ 0.10.
the scaffold which could further aid tissue regeneration. 27 Another benefit of the EGF-ELP fusion protein is the drug and drug carrier are one and produced as one by bacteria, removing the need to physically or chemically conjugate EGF with a delivery vehicle.
The biological activity assays using human skin fibroblasts, A549 cancer cells, and A431 cancer cells all show the EGF-ELP retains the biological activity of EGF. In particular, the proliferation of fibroblast and induced migration of A549 cells demonstrates the potential for the EGF-ELP to be used for wound regeneration as fibroblast and epithelial cell proliferation and migration are important components of the wound healing process, such as granulation tissue formation and epithelialization. [28] [29] [30] Although, the treatments did not appear to show any dose dependence, which is likely due to a dose threshold being reached using EGF-ELP. Future studies will use lower concentrations of EGF-ELP to determine the most effective concentration. Additionally, further experiments will be necessary to compare the regenerative capabilities of the EGF-ELP and rEGF.
The enhanced migration of A549 cells treated with EGF is indicated by the apparent epithelialto-mesenchymal transition (EMT) of the cells and the increased distance between cells. The elongated nature of the A549 cells treated with EGF is indicative of EMT, which is an important step in tissue repair, as it coincides with a decrease in cell-to-cell adhesion and increase in cell migratory capability. 31, 32 Additionally, EGF has been shown to induce EMT in epithelial cells. 33 The ability to create ELP fusion proteins that retain the biological activity of peptides and the inverse phase transition property of ELPs makes them ideal candidates for localized drug delivery. There are a number of ways ELP fusion proteins can be utilized for local drug delivery. One method has seen the creation of coacervate drug depots via aggregation of ELP fusion proteins for treatment of osteoarthritis 34 and neuroinflammation. 35 Furthermore, keratinocyte growth factor-ELP fusion protein coacervates have been used in conjunction with fibrin hydrogels for delivery of keratinocyte growth factor-ELP fusions to wounds in animal models. 19 Another method utilized for the local delivery of ELP fusion proteins is chemically cross-linking ELP domains to create a threedimensional scaffold. 27 In addition to possessing the biological activity of EGF, the EGF-ELP retained the ability to undergo reversible inverse phase transition, though the phase transition displayed some hysteresis during cooling. This is not unusual for some ELPs as the kinetics for transitioning and re-solubilization are different. Indeed, DLS data and the western blot show that some aggregates were still present when the transitioned protein solution was cooled to below the transition temperature. This could be attributed to the hydrophobicity of EGF or the secondary structure of EGF in the fusion may also play a role. Further studies are needed to identify the cause of this hysteresis behavior.
Even though the fusion protein displayed hysteresis, the EGF-ELP was purified via ITC though some protein was lost during the purification steps. This could provide a relatively simple and inexpensive purification technique for rEGF when compared to affinity chromatography methods. We believe that the hysteresis of EGF-ELP can be addressed by fusing a more hydrophilic ELP to EGF. This may help in increasing the yield of EGF-ELP; however, care must be taken in choosing the ELP sequence as a higher hydrophilic ELP may result in an increase in the transition temperature making the transition of EGF-ELP difficult.
In summary, we were successfully able to create a fusion protein that retained the biological activity of EGF as well as the physical phase transition property of ELPs. The ELP portion of the fusion property functions as a polymeric backbone imparting not only temperature-responsive behavior but also as scaffold for tissue engineering and drug delivery. Thus, it can serve as a biologically active biomaterial with potential application in tissue engineering (as a scaffold) or wound healing (as drug delivery vehicle). Finally, the ELP aggregating behavior enables the delivery of combination therapy involving multiple growth factors and bioactive peptides. Thus, this novel biomaterial will have far-reaching impact in tissue engineering and drug delivery.
